TFE3-rearranged nonmelanotic renal PEComa: a case series expanding their phenotypic and fusion landscape

被引:2
|
作者
Agaimy, Abbas [1 ]
Acosta, Andres M. [2 ]
Cheng, Liang [3 ,4 ]
Collins, Katrina [2 ]
Fridman, Eddie [5 ]
Schubart, Christoph [1 ]
Williamson, Sean R. [6 ]
Hartmann, Arndt [1 ]
Trpkov, Kiril [7 ,8 ]
机构
[1] Friedrich Alexander Univ Erlangen Nuremberg, Comprehens Canc Ctr, European Metropolitan Area Erlangen Nuremberg CCC, Inst Pathol,Erlangen Univ Hosp, Erlangen, Germany
[2] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN 46202 USA
[3] Brown Univ, Legorreta Canc Ctr, Dept Pathol & Lab Med, Dept Surg Urol,Warren Alpert Med Sch, Providence, RI 02912 USA
[4] Brown Univ Hlth, Providence, RI USA
[5] Tel Aviv Univ, Affiliated Fac Med, Sheba Med Ctr, Dept Diagnost Pathol, Tel Aviv, Israel
[6] Cleveland Clin, Robert J Tomsich Pathol & Lab Med Inst, Dept Anat Pathol, Cleveland, OH 44106 USA
[7] Alberta Precis Labs, Diagnost & Mol Pathol, Calgary, AB, Canada
[8] Univ Calgary, Calgary, AB, Canada
关键词
gene fusions; MiTF pathway; molecular profiling; oncogenes; RCC; targeted therapy; POLYCYSTIC KIDNEY-DISEASE; TFE3; NEOPLASMS; CARCINOMA; TUMOR; ANGIOMYOLIPOMA; EXPRESSION; FEATURES; VARIANT;
D O I
10.1111/his.15304
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
AimsA subset of exceptionally rare primary renal perivascular epithelioid cell tumours (PEComas) that harbour Xp11.2 translocation have been reported, but no larger series devoted to this topic have been published.Methods and ResultsWe describe the clinicopathological and molecular features of 10 renal PEComas, collected from our routine and consultation files. There were five female and five male patients aged 14-65 (median: 32 years). One patient had a history of childhood neuroblastoma, but no patients were known to have a tuberous sclerosis complex or other hereditary disorder. Complete surgical excision was the treatment for all patients. The available follow-up in five patients indicated a favourable outcome in 4/5 cases. Tumour size ranged from 2.8 to 15.2 cm (median, 5.2 cm). Immunohistochemistry revealed consistently strong TFE3 expression in all tumours, whereas PAX8 and keratin cocktails were uniformly negative. Other positive markers included HMB45 (7/9 tumours), CathepsinK (7/9 tumours), and CD117 (KIT) (3/5 tumours). TFE3 rearrangements were detected in 8/9 tumours (by targeted RNA sequencing in seven and by FISH in one). The identified fusion partners included SFPQ (n = 2) and one tumour each with ASPSCR1, ZC3H4, MED15, RBMX, and PRCC. One tumour that lacked TFE3 rearrangement by next-generation sequencing (NGS) and fluorescence in situ hybridization (FISH) revealed a large intrachromosomal deletion involving PKD1 and TSC2 by DNA-based NGS.ConclusionThis study highlights the morphologic and genetic diversity of TFE3-rearranged primary renal PEComas and underlines the value of surrogate TFE3 immunohistochemistry in identifying them. The lack of PAX8 and keratin expression represents the mainstay for distinguishing these tumours from MiTF-associated renal cell carcinomas. In addition, we report rare (ZC3H4, RBMX) and novel (MED15) TFE3 fusion partners in PEComa. TFE3-rearranged renal PEComas display high cytomorphological diversity with clear, eosinophilic, or mixed cell types, but lack significant anaplasia and pleomorphism. Their phenotypic diversity is paralleled by the diversity of their TFE3 gene fusion partner landscape. Homogeneous and strong TFE3 expression is characteristic. Despite their molecular dichotomy (MiTF vs. mTOR-altered), pathway convergence is reflected in strong TFE3 expression in TSC-altered PEComas. Contiguous PKD1 codeletion may explain the gross cystic pattern in TSC2 altered PEComas. image
引用
收藏
页码:783 / 793
页数:11
相关论文
共 50 条
  • [21] Patients with ASPSCR1-TFE3 fusion achieve better response to ICI based combination therapy among TFE3-rearranged renal cell carcinoma
    Zhao, Junjie
    Tang, Yanfeng
    Hu, Xu
    Yin, Xiaoxue
    Chen, Yuntian
    Chen, Junru
    Liu, Haoyang
    Liu, Haolin
    Liang, Jiayu
    Zhang, Xingming
    Zhao, Jinge
    Zhu, Sha
    Ni, Yuchao
    Wang, Zhipeng
    Dai, Jindong
    Wang, Zilin
    Zhang, Yaowen
    Yao, Jin
    Chen, Ni
    Shen, Pengfei
    Liu, Zhenhua H.
    Zeng, Hao
    Sun, Guangxi X.
    MOLECULAR CANCER, 2024, 23 (01)
  • [22] Case Reports of TFE3-Rearranged Renal Cell Carcinoma: FDG-PET Uptake Might Help Diagnosis
    Murakami, Sho
    Nagawa, Keita
    Inui, Takanori
    Yamamoto, Aya
    Suzuki, Mizuka
    Koga, Fumitaka
    Motoi, Toru
    Takaki, Yasunobu
    JOURNAL OF KIDNEY CANCER AND VHL, 2023, 10 (03): : 61 - 68
  • [23] Exploring TFE3-Rearranged Renal Cell Carcinoma: A Case Study showing minimal expression of PAX-8
    Sustache, J. M. Rivera
    Bhalla, R.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 162 : S143 - S143
  • [24] Secondary TFE3-Rearranged Renal Cell Carcinoma in a Chinese Girl Treated for Wilms Tumor: Case Report and Literature Review
    Chu, Jing
    Chen, Lian
    FETAL AND PEDIATRIC PATHOLOGY, 2024, 43 (06) : 500 - 509
  • [25] TFE3-rearranged hepatic epithelioid hemangioendothelioma-a case report with immunohistochemical and molecular study
    Kuo, Fang-Ying
    Huang, Hsuan-Ying
    Chen, Chao-Long
    Eng, Hock-Liew
    Huang, Chao-Cheng
    APMIS, 2017, 125 (09) : 849 - 853
  • [26] Diagnostic approach in TFE3-rearranged renal cell carcinoma: a multi-institutional international survey
    Akgul, Mahmut
    Williamson, Sean R.
    Ertoy, Dilek
    Argani, Pedram
    Gupta, Sounak
    Calio, Anna
    Reuter, Victor
    Tickoo, Satish
    Al-Ahmadie, Hikmat A.
    Netto, George J.
    Hes, Ondrej
    Hirsch, Michelle S.
    Delahunt, Brett
    Mehra, Rohit
    Skala, Stephanie
    Osunkoya, Adeboye O.
    Harik, Lara
    Rao, Priya
    Sangoi, Ankur R.
    Nourieh, Maya
    Zynger, Debra L.
    Smith, Steven Cristopher
    Nazeer, Tipu
    Gumuskaya, Berrak
    Kulac, Ibrahim
    Khani, Francesca
    Tretiakova, Maria S.
    Vakar-Lopez, Funda
    Barkan, Guliz
    Molinie, Vincent
    Verkarre, Virginie
    Rao, Qiu
    Kis, Lorand
    Panizo, Angel
    Farzaneh, Ted
    Magers, Martin J.
    Sanfrancesco, Joseph
    Perrino, Carmen
    Gondim, Dibson
    Araneta, Ronald
    So, Jeffrey S.
    Ro, Jae Y.
    Wasco, Matthew
    Hameed, Omar
    Lopez-Beltran, Antonio
    Samaratunga, Hemamali
    Wobker, Sara E.
    Melamed, Jonathan
    Cheng, Liang
    Idrees, Muhammad T.
    JOURNAL OF CLINICAL PATHOLOGY, 2021, 74 (05) : 291 - 299
  • [27] A nomogram based on TFE3 IHC results and clinical factors as a preliminary screening scheme for TFE3-rearranged renal cell carcinoma
    Li, Pengju
    Xu, Quanhui
    Chen, Minyu
    Zhu, Jiangquan
    Wang, Yinghan
    Mumin, Mukhtar A.
    Huang, Kangbo
    Jiang, Zeying
    Liang, Hui
    Deng, Qiong
    Wang, Zhu
    Liao, Bing
    Chen, Wenfang
    Cao, Yun
    Cao, Jiazheng
    Luo, Junhang
    CANCER MEDICINE, 2024, 13 (05):
  • [28] Orbital TFE3-Rearranged Perivascular Epithelioid Cell Tumor: A Case Report and Review of the Literature
    Feu-Basilio, Silvia
    Matas, Jessica
    Dotti-Boada, Marina
    Toll, Agustin
    Larque, Ana-Belen
    Pigem, Ramon
    Ortiz-Perez, Santiago
    AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2021, 43 (12) : E263 - E266
  • [29] MAPK1IP1L::TFE3-rearranged renal cell carcinoma: a novel fusion adding to the differential diagnosis of oncocytic renal neoplasms
    Cheng, Anne V.
    Wu, Douglas J.
    Friedman, Lisa Aviva
    Chan, Emily
    Williamson, Sean R.
    Galea, Laurence A.
    Sangoi, Ankur R.
    VIRCHOWS ARCHIV, 2025,
  • [30] Molecular Characterization of TFE3-Rearranged Renal Cell Carcinoma: A Comparative Study With Papillary and Clear Cell Renal Cell Carcinomas
    Weia, Shuanzeng
    Krauseb, Harris B.
    Geynismanc, Daniel M.
    Elliottb, Andrew
    Kutikovd, Alexander
    Uzzod, Robert G.
    Peia, Jianming
    Baratae, Pedro
    Carneirof, Benedito
    Heathg, Elisabeth
    Ryanh, Charles
    Farrellb, Alex
    Nabhanb, Chadi
    Ali-Fehmii, Rouba
    Naqashj, Abdul Rafeh
    Arganik, Pedram
    McKayl, Rana R.
    MODERN PATHOLOGY, 2024, 37 (02)